GLP-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, have transformed obesity and type 2 diabetes mellitus management through robust weight loss and metabolic benefits. GLP-1 RAs produce substantial weight loss through appetite suppression, delayed gastric emptying, and metabolic modulation. As these agents increasingly enter aesthetic medicine ecosystems - where weight management, body contouring, and skin health intersect with patient expectations about appearance - clinicians face dual questions: Do GLP-1 RAs represent a therapeutic breakthrough for patients seeking aesthetic improvements, or do they risk catalyzing unrealistic body ideals and exacerbating societal pressures around weight and appearance? This review synthesizes mechanistic, clinical, psychosocial, ethical, and regulatory dimensions of GLP-1 RA use in aesthetic contexts, drawing on a broad corpus of literature including recent reviews and primary studies, as well as the provided candidate references and additional sources. We examine (1) pharmacology and clinical efficacy for weight reduction and body composition, (2) esthetic implications of rapid weight loss, including facial volume changes and skin effects, (3) ethical and societal considerations surrounding body ideals, (4) risk–benefit and safety concerns in cosmetic and non-diabetic populations, (5) integration with other aesthetic modalities and multidisciplinary care, and (6) practical guidance for clinicians operating Ozempicin-like aesthetic clinics. We conclude with a framework for responsible, patient-centered deployment of GLP-1–based therapies within aesthetic medicine, emphasizing informed consent, psychosocial screening, realistic expectation management, and equitable access.
Kowalczyk et al. (Mon,) studied this question.